

A Functional Composite Endpoint to Characterize Disease Progression in Patients with Active or Non-active Secondary Progressive Multiple Sclerosis

Ludwig Kappos¹, Bruce A. C. Cree², Amit Bar-Or³, Ralf Gold⁴, Patrick Vermersch⁵, Robert J. Fox⁶, Ralph H. B. Benedict⁷, Sophie Arnould⁸, Goeril Karlsson⁸, Daniela Piani Meier⁸, Thomas Hach⁸, Gavin Giovannoni⁹

Oral presentation

¹Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland; ²UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA; ³Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; ⁴Department of Neurology, St Josef-Hospital/Ruhr-University Bochum, Bochum, Germany; ⁵Univ. Lille, INSERM U1172, CHU Lille, Lille, France; ⁶Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland, OH, USA; ⁷Department of Neurology, University at Buffalo, Buffalo, NY, USA; ⁸Novartis Pharma AG, Basel, Switzerland; ⁹Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

Oral Presentation at the 7th Congress of the European Academy of Neurology, June 19-22, 2021



Scan to download a copy of this presentation

Disclosures

Ludwig Kappos' institution (University Hospital Basel) has received the following exclusively for research support: Steering committee, advisory board, and consultancy fees (Actelion, Bayer HealthCare, Biogen, BMS, Genzyme, Janssen, Merck, Novartis, Roche, Sanofi, Santhera, TG Therapeutics); Speaker fees (Bayer HealthCare, Biogen, Merck, Novartis, Roche, and Sanofi); Support of educational activities (Allergan, Bayer HealthCare, Biogen, CSL Behring, Desitin, Genzyme, Merck, Novartis, Roche, Pfizer, Sanofi, Shire, and Teva); License fees for Neurostatus products; And grants (Bayer HealthCare, Biogen, European Union, InnoSwiss, Merck, Novartis, Roche, Swiss MS Society, and Swiss National Research Foundation). **Bruce A. C. Cree** has received personal compensation for consulting from Akili, Alexion, Atara, Autobahn, Biogen, EMD Serono, Novartis, Sanofi, Therini and TG Therapeutics and received research support from Genentech. **Amit Bar-Or** has participated as a speaker in meetings sponsored by and received consulting fees and/or grant support from Janssen/ Actelion; Atara Biotherapeutics, Biogen Idec, Celgene/Receptos, Roche/Genentech, Medimmune, Merck/EMD Serono, Novartis, and Sanofi Genzyme. **Ralf Gold** has received compensation for serving as a consultant or speaker from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis and Teva Neuroscience. He, or the institution he works for, has received research support from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis and Teva Neuroscience. He has also received honoraria as a Journal Editor from SAGE and Thieme Verlag. **Patrick Vermersch** has received honoraria and consulting fees from Biogen Idec, Sanofi Genzyme, Bayer, Novartis, Merck Serono, GlaxoSmithKline and Almirall and research support from Biogen Idec, Sanofi Genzyme, Bayer and Merck Serono. **Robert J. Fox** has received personal consulting fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis and Teva. He has served on advisory committees for Actelion, Biogen, Immunic and Novartis and received clinical trial contract and research grant funding from Biogen and Novartis. **Ralph H. B. Benedict** has received has received consultation or speaking fees from Bristol Myer Squibb, Biogen, Merck, EMD Serono, Roche, Verasci, Immune Therapeutics, Novartis, and Sanofi Genzyme; **Gavin Giovannoni** is a steering committee member on the daclizumab trials for AbbVie, the BG12 and daclizumab trials for Biogen, the fingolimod and siponimod trials for Novartis, the laquinimod trials for Teva and the ocrelizumab trials for Roche. He has also received consultancy fees for advisory board meetings for the oral cladribine trials for Merck KGaA, Genzyme-Sanofi, and in relation to the DSMB activities for Synthon BV as well as honoraria for speaking at the Physicians' Summit and several medical education meetings. He is also the Co-Chief Editor of Multiple Sclerosis and Related Disorders (Elsevier).

Sophie Arnould, Goeril Karlsson, Daniela Piani-Meier, and Thomas Hach are employees of Novartis.

Funding source: This study is supported by Novartis Pharma AG, Basel, Switzerland.

Acknowledgment: Medical writing support was provided by **Bhavesh Kshirsagar** and **Sreelatha Komatireddy** (employees of Novartis Healthcare Pvt. Ltd., Hyderabad, India). The final responsibility for the content lies with the authors.

Background

- Composite endpoints (CEPs) have the potential to capture disease progression more comprehensively as they account for functions that are not, or not optimally, captured by a single endpoint alone¹
- With CEPs, increment of the number of events is expected to increase power/statistical efficiency
- The phase 3 EXPAND study in patients with SPMS² evaluated the efficacy of siponimod on confirmed disability progression (CDP) as measured by the primary outcome (EDSS), cognitive processing speed (by SDMT) and several other outcomes, including upper limb function (9HPT) and ambulation (T25FWT)^{2,3}
- A previous analysis combining SDMT and EDSS, resulted in higher sensitivity to detect treatment effects in SPMS⁴
- In the current analysis, 9HPT and T25FWT are included with SDMT and EDSS in the construction of novel CEP to determine treatment effects on the functional domains of high clinical relevance in SPMS

Objective

To characterize disease progression using novel CEPs relevant to SPMS and evaluate their performance in active and non-active SPMS patients

Methods

This post hoc analysis included data from patients with SPMS from the Phase 3 EXPAND core study:

Overall population	Subgroup of patients with active disease ^a	Subgroup of patients with non-active disease ^b
Siponimod: N=1099 Placebo: N=546	Siponimod: N=516 Placebo: N=263	Siponimod: N=557 Placebo: N=270

Statistical analysis:

- Time-to-6-month confirmed disease progression was analyzed using the Cox proportional hazards model with treatment, country, baseline EDSS score, and SPMS subgroups (with/without superimposed relapses, baseline definition) as covariates
- Risk reduction was derived as $(1 - \text{hazard ratio}) * 100$


^aDefined as the presence of at least one relapse in the 2 years before screening and/or ≥ 1 Gd+ T1 lesion at baseline.

^bDefined as no relapse in the 2 years prior to screening and no Gd+ T1 lesion at baseline.

Methods


Investigated endpoints

Compared treatment effect on reducing time-to-6-month confirmed disease progression based on EDSS alone, CEP1 and CEP2



Results

Contribution of each individual component by CEP1 in overall, active SPMS and non-active SPMS patients



Overlap (n/N'): is the percentage of patients experiencing 6-month confirmed progression on 2 or 3 endpoints and N' is the total number of events

- The three endpoints, EDSS, SDMT and 9HPT, appear to capture distinct aspects of 6-month CDP with only minor overlap
- More overlap of the endpoints (i.e. more dimensions of disease progression) was observed in the placebo-treated active SPMS patients


The figures are indicative rather than actual representation of the data.

9HPT, 9-Hole Peg Test; CDP, confirmed disability progression; CEP, composite endpoint; EDSS, Expanded Disability Status Scale; pt, points; SDMT, Symbol Digit Modalities Test; SPMS, secondary progressive multiple sclerosis; T25FWT, Timed 25-Foot Walk test

Results

Treatment effect as measured by risk reduction of disability progression with EDSS alone, CEP1 and CEP2

Time to
6-month CDP



- Siponimod was associated with significant risk reductions (range: 25%–37%) versus placebo in the overall and active SPMS populations
- In non-active SPMS patients, the trend favoring siponimod treatment was more pronounced with the composite endpoints
- The CEPs yield smaller confidence interval and thus greater power to assess treatment difference
- Addition of T25FWT in CEP2 did not further reduce the width of CIs (i.e. T25FWT didn't increase the precision of the HR estimate)

*(EDSS and/or SDMT and/or 9HPT and/or T25FWT, if BL-EDSS ≤5.5) or (EDSS and/or SDMT and/or 9HPT, if BL-EDSS >5.5) p-value. CEP1, 6-month CDP events based on EDSS and/or SDMT and/or 9-HPT; CEP2, 6-month CDP events based on EDSS and/or SDMT and/or 9HPT and/or T25FWT. BL, baseline; CDP, confirmed disability progression; CEP, composite endpoints; CI, confidence interval; EDSS, Expanded Disability Status Scale; HR, hazard ratio; SPMS, secondary progressive multiple sclerosis; T25FWT, Timed 25-Foot Walk test

Results

Percentage of patients with CDP based on EDSS alone, CEP1 and CEP2 – Kaplan Meier (KM) estimates

Time to 6m-CDP


EDSS alone

CEP1

(EDSS and/or SDMT and/or 9HPT)

CEP2

(EDSS and/or SDMT and/or 9HPT and/or T25FWT*)




With EDSS alone, the percentage (KM estimates) of placebo patients with CDP at month 18 was 26% (Overall), 28.5% (active) and 24.7% (non-active); with CEP1, percentage with CDP events was incremented to 43% (overall), 45% (active) and 41% (non-active)

*(EDSS and/or SDMT and/or 9HPT and/or T25FWT, if BL-EDSS ≤5.5) or (EDSS and/or SDMT and/or 9HPT, if BL-EDSS >5.5) p-value. CEP1, 6-month CDP events based on EDSS and/or SDMT and/or 9-HPT; Numbers in the figure represent HR [95% CI]; p-value. CEP1, 6 month CDP events based on EDSS and/or SDMT and/or 9-HPT; CEP2, 6-month CDP events based on EDSS and/or SDMT and/or 9HPT and/or T25FWT 6m-CDP, 6 month confirmed disability progression; BL, baseline; CEP, composite endpoints; CI, confidence interval; EDSS, Expanded Disability Status Scale; HR, hazard ratio SPMS, secondary progressive multiple sclerosis

Results

Sample size and power calculation



Singleton: E6: 6-Month CDP based on EDSS

Composite endpoint (CEP): CEP1: EDSS and/or SDMT and/or 9HPT ;

CEP2: (EDSS and/or SDMT and/or 9HPT and/or T25FWT, if BL-EDSS ≤5.5) or (EDSS and/or SDMT and/or 9HP, if BL-EDSS >5.5)


Method: The Schoenfeld's [Collet, 2003] formulae was used to calculate number of events over a range of values for the Hazard ratio and CDP rates in their placebo arm.

Assumptions : Superiority of active treatment vs placebo; two-sided test at the 5% significance level; 80% power; 1:1 allocation ratio; fixed follow-up of 24 months (i.e. Onset of CDP within 18 months); To account for premature withdrawal, a safety margin of 15% was added to this number.

- CEPs could be advantageously used to reduce sample size by >600 subjects in future trials
- It may not be advantageous to expand the single EDSS endpoint in active disease
- A study in SPMS patients without active disease may not be feasible if based on the single EDSS endpoint instead of a composite

Conclusions

- Adding SDMT and 9HPT to the EDSS assessment (CEP1) allowed detection of treatment effects on a broader spectrum of functions in patients with SPMS compared with EDSS alone, in both patients with active and non-active disease
- Addition of T25FWT did not further increase test sensitivity
- Siponimod treatment effect with the two composite endpoints was consistent with that observed with the anchor EDSS endpoint, i.e. statistically significant risk reductions in the overall EXPAND population and in patients with active disease
- However, a more pronounced trend was observed in non-active SPMS applying CEP1 and CEP2, indicating that the composite endpoints which cover different functional domains capture treatment effects more comprehensively
- Using composite endpoints could help to reduce the sample sizes by more than 600 patients in future studies in full SPMS. In non-active SPMS, sample size could be reduced (as compared to EDSS alone) to a feasible range



Thank you